-
Mashup Score: 3The Benefit to Radium-223 Added to Cabozantinib for Patients With Renal Cell Carcinoma With Bone Metastasis, RadiCaL - Rana McKay - 1 year(s) ago
Rana McKay joins Alicia Morgans to discuss the RadiCaL trial, a study looking at metastatic kidney cancer and the use of radium in that population. The trial is a phase II trial, taking patients with renal cell carcinoma (RCC) with bone metastases and randomizing them 1:1 to receive radium with cabozantinib versus cabozantinib alone. The primary endpoint of RadiCaL is a reduction in symptomatic…
Source: UroTodayCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 31Avascular spaces in radical hysterectomy - 1 year(s) ago
The most common cancer in women worldwide is cervical cancer. For early-stage disease the standard treatment is radical hysterectomy. One of the main issues faced by surgeons performing a radical hysterectomy is the wide variation in the terminology used to define the procedure and the nomenclature used to describe the anatomical spaces critical to the success of the surgery. The aim of this…
Categories: Latest Headlines, Oncologists2Tweet-
RT @IJGConline: Refresh your #radical #hysterectomy anatomy with the comprehensive review on #avascular spaces @ https://t.co/akW9pE9Wbh @…
-
-
Mashup Score: 2
IKCS 2022 data from the RADICAL trial of radium-223 and cabozantinib, advanced renal cell carcinoma (RCC) with bone metastases, vascular endothelial growth factor (VEGF) receptor and MET kinase inhibitor cabozantinib.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
A randomized trial of radium-223 dichloride and cabozantinib in pts with advanced #RenalCellCarcinoma with bone metastases (#RADICAL / #Alliance A031801). Presentation by @DrRanaMcKay @UCSanDiego. #IKCSNA22 coverage by @WallisCJD @UofT > https://t.co/zVMMkyMi2D @kidneycancer https://t.co/fOTei4NXVi
-
-
Mashup Score: 1
Read it now on PracticeUpdate.com
Source: PracticeUpdateCategories: Hem/Oncs, Latest HeadlinesTweet-
Metastasis-Directed Radiation Therapy (MDRT) After #radical #cystectomy for #bladdercancer (n=52)-consolidative MDRT associated with durable benefit (2-yr PFS 19%)-majority in context of #Immunotherapy-@UTSWUrology https://t.co/S7CKO5EtTG @practiceupdate
-
-
Mashup Score: 0Radical surgery for recurrent pulmonary artery sarcoma with four-year survival - PubMed - 3 year(s) ago
Primary pulmonary artery (PA) sarcoma (PAS) is a rare disease with poor prognosis. Radical resection provides the best curative chances. Our 60-year old male patient underwent PAS excision with pericardial patch repair of the main PA in 2017, but required reoperation in 2019 due to recurrence. Total …
Source: PubMedCategories: Latest Headlines, PulmonologyTweet-
#Radical #surgery for #recurrent #pulmonary #artery #sarcoma with four-year survival https://t.co/Rx5X4UIB1D https://t.co/R4I8gr0YdC
-
-
Mashup Score: 13
Every day, our bodies face a bombardment of UV rays, ozone, cigarette smoke, industrial chemicals and other hazards.
Source: medicalxpress.comCategories: General Medicine News, Latest HeadlinesTweet-
Exposure to pollutants, increased free-#radical damage speeds up aging @nature https://t.co/HHbsUVF2iT
-
-
Mashup Score: 2“Melanincholy”: A Qualitative Exploration of Youth Media Use, Vicarious Racism, and Perceptions of Health - 3 year(s) ago
We sought to (1) characterize teens’ experiences with news and social media, focusing on news depicting racism, (2) assess youth perceptions of how th…
Source: www.sciencedirect.comCategories: Latest Headlines, PediatricsTweet-
. @rianaelyse on @CNN reminds us that #thorniness we feel after the #chauvinverdict reminds us that we still FEEL & aren't #desensitized to what's happening around us, as @AlyssaCohenMD found in teens. https://t.co/EYiCD3Om7p But this means we need to practice #radical #selfcare https://t.co/3kdPgE452E
-
-
Mashup Score: 2The Alliance Trial A031801 - RadiCal a Trial of Radium-223 in Patients with Renal Cell Carcinoma, - Rana McKay - 3 year(s) ago
Potentially practice-changing study sponsored by the National Cancer Institute — A discussion with Rana McKay, MD, principal investigator. Radium-223 (223Ra) is an alpha particle-emitting radioactive agent that received Federal Drug Administration (FDA) approval in 2013 to treat patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
The Alliance Foundation trial - #RadiCal a trial of radium-223 in patients with #RenalCellCarcinoma. @DrRanaMcKay @UCSanDiego joins @CaPsurvivorship @NUFeinbergMed for a discussion on UroToday. #WatchNow > https://t.co/nhM6z3jKyZ @ALLIANCE_org @theNCI https://t.co/lOQFJoqkPi
-
-
Mashup Score: 0The Alliance Trial A031801 - RadiCal a Trial of Radium-223 in Patients with Renal Cell Carcinoma, - Rana McKay - 3 year(s) ago
Potentially practice-changing study sponsored by the National Cancer Institute — A discussion with Rana McKay, MD, principal investigator. Radium-223 (223Ra) is an alpha particle-emitting radioactive agent that received Federal Drug Administration (FDA) approval in 2013 to treat patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
The Alliance Foundation trial - #RadiCal a trial of radium-223 in patients with #RenalCellCarcinoma. @DrRanaMcKay @UCSanDiego joins @CaPsurvivorship @NUFeinbergMed for a discussion on UroToday. #WatchNow > https://t.co/nhM6z3jKyZ @ALLIANCE_org @theNCI https://t.co/ihCQlP8uwC
-
-
Mashup Score: 0The Alliance Foundation Trial - RadiCal a Trial of Radium-223 in Patients with Renal Cell Carcinoma, - Rana McKay - 3 year(s) ago
Potentially practice-changing study sponsored by the National Cancer Institute — A discussion with Rana McKay, MD, principal investigator. Radium-223 (223Ra) is an alpha particle-emitting radioactive agent that received Federal Drug Administration (FDA) approval in 2013 to treat patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
The Alliance Foundation trial - #RadiCal a trial of radium-223 in patients with #RenalCellCarcinoma. @DrRanaMcKay @UCSanDiego joins @CaPsurvivorship @NUFeinbergMed for a discussion on UroToday. #WatchNow > https://t.co/nhM6z3jKyZ @ALLIANCE_org @theNCI https://t.co/r7SDkB2FAr
-
@DrRanaMcKay @UCSanDiego and @CaPsurvivorship @DanaFarber discuss the #RadiCaL trial, a phase II study exploring the use of radium in #mRCC with bone metastases and the benefit of Radium-223 with Cabozantinib vs cabozantinib alone. #WatchNow > https://t.co/QlEGZlDf4r @theNCI https://t.co/vot9rVOAkT